1
|
Park SA, Lee Y, Hwang H, Lee JH, Kang YJ, Kim Y, Jin C, An HJ, Oh YJ, Hinterdorfer P, Kim E, Choi S, Ko K. Fc engineered anti-virus therapeutic human IgG 1 expressed in plants with altered binding to the neonatal Fc receptor. Biotechnol J 2024; 19:e2300552. [PMID: 38528347 DOI: 10.1002/biot.202300552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2023] [Revised: 03/07/2024] [Accepted: 03/09/2024] [Indexed: 03/27/2024]
Abstract
Production of therapeutic monoclonal antibody (mAb) in transgenic plants has several advantages such as large-scale production and the absence of pathogenic animal contaminants. However, mAb with high mannose (HM) type glycans has shown a faster clearance compared to antibodies produced in animal cells. The neonatal Fc receptor (FcRn) regulates the persistence of immunoglobulin G (IgG) by the FcRn-mediated recycling pathway, which salvages IgG from lysosomal degradation within cells. In this study, Fc-engineering of antirabies virus therapeutic mAb SO57 with the endoplasmic reticulum (ER)-retention peptide signal (Lys-Asp-Glu-Leu; KDEL) (mAbpK SO57) in plant cell was conducted to enhance its binding activity to human neonatal Fc receptor (hFcRn), consequently improve its serum half-life. Enzyme-linked immunosorbent assay (ELISA) and Surface plasmon resonance assay showed altered binding affinity of the Fc region of three different mAbpK SO57 variants [M252Y/S254T/T256E (MST), M428L/N434S (MN), H433K/N434F (HN)] to hFcRn compared to wild type (WT) of mAbpK SO57. Molecular modeling data visualized the structural alterations in these mAbpK SO57. All of the mAbpK SO57 variants had HM type glycan structures similar to the WT mAbpK SO57. In addition, the neutralizing activity of the three variants against the rabies virus CVS-11 was effective as the WT mAbpK SO57. These results indicate that the binding affinity of mAbpK SO57 variants to hFcRn can be modified without alteration of N-glycan structure and neutralization activity. Taken together, this study suggests that Fc-engineering of antirabies virus mAb can be applied to enhance the efficacy of therapeutic mAbs in plant expression systems.
Collapse
Affiliation(s)
- Sol-Ah Park
- Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea
| | - Yoonji Lee
- College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea
| | - Hyunjoo Hwang
- Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea
| | - Jeong Hwan Lee
- Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea
| | - Yang Joo Kang
- Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea
| | - Yerin Kim
- Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea
| | - Caiquan Jin
- Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea
| | - Hyun Joo An
- Graduate School of Analytical Science and Technology, Chungnam National University, Daejeon, Republic of Korea
| | - Yoo Jin Oh
- Department of Applied Experimental Biophysics, Johannes Kepler University Linz, Linz, Austria
| | - Peter Hinterdorfer
- Department of Applied Experimental Biophysics, Johannes Kepler University Linz, Linz, Austria
| | - Eunhye Kim
- Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea
| | - Sun Choi
- Global AI Drug Discovery Center, College of Pharmacy and Graduate School of Pharmaceutical Sciences, Ewha Womans University, Seoul, Republic of Korea
| | - Kisung Ko
- Department of Medicine, BioSystems Design Lab, College of Medicine, Chung-Ang University, Dongjak-gu, Seoul, Republic of Korea
| |
Collapse
|
2
|
Nikolouli E, Reichstein J, Hansen G, Lachmann N. In vitro systems to study inborn errors of immunity using human induced pluripotent stem cells. Front Immunol 2022; 13:1024935. [DOI: 10.3389/fimmu.2022.1024935] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Accepted: 10/28/2022] [Indexed: 11/18/2022] Open
Abstract
In the last two decades, the exponential progress in the field of genetics could reveal the genetic impact on the onset and progression of several diseases affecting the immune system. This knowledge has led to the discovery of more than 400 monogenic germline mutations, also known as “inborn errors of immunity (IEI)”. Given the rarity of various IEI and the clinical diversity as well as the limited available patients’ material, the continuous development of novel cell-based in vitro models to elucidate the cellular and molecular mechanisms involved in the pathogenesis of these diseases is imperative. Focusing on stem cell technologies, this review aims to provide an overview of the current available in vitro models used to study IEI and which could lay the foundation for new therapeutic approaches. We elaborate in particular on the use of induced pluripotent stem cell-based systems and their broad application in studying IEI by establishing also novel infection culture models. The review will critically discuss the current limitations or gaps in the field of stem cell technology as well as the future perspectives from the use of these cell culture systems.
Collapse
|